Vasodilatory shock is a critical manifestation of cardiovascular failure. There is uncontrolled vasodilation and vascular hyporesponsiveness to endogenous vasoconstrictors, causing the failure of physiologic vasoregulatory mechanisms. Unfortunately, only few randomized studies exist to guide clinical management and hemodynamic stabilization in patients who do not respond to the standard approach of managing vasodilatory shock. The present review offers the latest updates in management of this important clinical entity and a guidance framework for future research.
Vincent JL, De Backer D. Circulatory shock. N Engl J Med 2013;369:1726–1734.
Hershey TB, Kahn JM. State sepsis mandates — A new era for regulation of hospital quality. N Engl J Med. 2017;376:2311–2313.
The death toll of sepsis in India [Internet]. Health Issues India. Available at https://www.healthissuesindia.com/2018/09/13/the-death-toll-of-sepsis-in-india/ [Last retrieved September 17, 2019].
Divatia JV, Amin PR, Ramakrishnan N, Kapadia FN, Todi S, Sahu S, et al. Intensive care in India: The Indian intensive care case mix and practice patterns study. Indian J Crit Care Med. 2016;20:216–225.
Schultz MJ, Dunser MW, Dondorp AM, Adhikari NK, Iyer S, Kwizera A, et al. Current challenges in the management of sepsis in ICUs in resource-poor settings and suggestions for the future. Intensive Care Med. 2017;43:612–624.
Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001;345:588–595.
Haseer Koya H, Paul M. Shock. [Updated 2018 Oct 27]. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2019 Jan. Available at: https://www.ncbi.nlm.nih.gov/books/NBK531492/ [Last retrieved September 17, 2019]
Bednarczyk JM, Fridfinnson JA, Kumar A, Blanchard L, Rabbani R, Bell D, et al. Incorporating dynamic assessment of fluid responsiveness into goal-directed therapy. Crit Care Med. 2017;45:1538–1545.
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock. Intensive Care Med. 2017;43:304–377.
Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Intensive Care Med. 2018;44:925–928.
Moeller C, Fleischmann C, Thomas-Rueddel D, Vlasakov V, Rochwerg B, Theurer P, et al. How safe is gelatin? A systematic review and meta-analysis of gelatin-containing plasma expanders vs crystalloids and albumin. J Crit Care. 2016;35:75–83.
Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–2256.
Aironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 2014;370:1412–1421.
De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362:779–789.
Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A. Vasopressors for the treatment of septic shock: Systematic review and meta-analysis. PLoS One. 2015;10(8):e0129305.
Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J, et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med. 2008;34:2226–2234.
Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877–887.
Polito A, Parisini E, Ricci Z, Picardo S, Annane D. Vasopressin for treatment of vasodilatory shock: An ESICM systematic review and meta-analysis. Intensive Care Med.2012;38:9–19.
del Greco F, Johnson DC. Clinical experience with angiotensin II in the treatment of shock. JAMA.1961;178:994–996.
Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, et al. Intravenous Angiotensin II for the Treatment of High-Output Shock (ATHOS trial): A pilot study. Crit Care. 2014;18:534.
Chawla LS, Russell JA, Bagshaw SM, Shaw AD, Goldstein SL, Fink MP, et al. Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): Protocol for a phase III, double-blind, randomised controlled trial. Crit Care Resusc. 2017;19:43–49.
FDA approves drug to treat dangerously low blood pressure: FDA news release 2017 [Internet]. US Food and Drug Administration. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-dangerously-low-blood-pressure [Last retrieved September 19, 2019].
Russell JA, Vincent J-L, Kjølbye AL, Olsson H, Blemings A, Spapen H, et al. Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Crit Care. 2017;21(1):213.
Park TK, Yang JH, Jeon K, Choi SH, Choi JH, Gwon HC, et al. Extracorporeal membrane oxygenation for refractory septic shock in adults. Eur J Cardiothorac Surg. 2015;47:e68–e74.
Von Bahr V, Hultman J, Eksborg S, Frenckner B, Kalzen H. Longterm survival in adults treated with extracorporeal membrane oxygenation for respiratory failure and sepsis. Crit Care Med. 2017;45:164–170.
Cheng A, Sun HY, Lee CW, Ko WJ, Tsai PR, Chuang YC, et al. Survival of septic adults compared with nonseptic adults receiving extracorporeal membraneoxygenation for cardiopulmonary failure: A propensity-matched analysis. J Crit Care. 2013;28:532.
Cole L, Bellomo R, Hart G, Journois D, Davenport P, Tipping P, et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002;30:100–106.
Payen D, Mateo J, Cavaillon JM, Fraisse F, Floriot C, Vicaut E, et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: A randomized controlled trial. Crit Care Med 2009;37:803–810.
Lukaszewicz AC, Payen D. Purification methods: A way to treat severe acute inflammation related to sepsis? Crit Care. 2013;17:159.
Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P. High-volume haemofiltration in human septic shock. Intensive Care Med. 2001;27:978–986.
Joannes-Boyau O, Honoré PM, Perez P, Bagshaw SM, Grand H, Canivet JL, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): A multicentre randomized controlled trial. Intensive Care Med. 2013;39:1535–1546.
Clark E, Molnar AO, Joannes-Boyau O, Honoré PM, Sikora L, Bagshaw SM. High-volume hemofiltration for septic acute kidney injury: A systematic review and meta-analysis. Crit Care. 2014;18:R7.
De Vriese AS, Colardyn FA, Philippé JJ, Vanholder RC, De Sutter JH, Lameire NH. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol. 1999;10:846–853.
Chang T, Tu YK, Lee CT, Chao A, Huang CH, Wang MJ, et al. Effects of polymyxin B hemoperfusion on mortality in patients with severe sepsis and septic shock: A systemic review, meta-analysis update, and disease severity subgroup meta-analysis. Crit Care Med. 2017;45(8):e858–e864.
Hawchar F, László I, Öveges N, Trásy D, Ondrik Z, Molnar Z. Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot study. J Crit Care. 2019;49:172–178.
Schädler D, Pausch C, Heise D, Meier-Hellmann A, Brederlau J, Weiler N, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial. PLoS One. 2017;12:e0187015.
Matson J, Zydney A, Honoré PM. Blood filtration: New opportunities and the implications of systems biology. Crit Care Resusc. 2004;6:209–217.
Friesecke S, Träger K, Schittek GA, Molnar Z, Bach F, Kogelmann K, et al. International registry on the use of the CytoSorb® adsorber in ICU patients: Study protocol and preliminary results. Med Klin Intensivmed Notfmed. 2017. doi: 10.1007/s00063-017-0342-5. [Epub ahead of print] Review.